SCHEDULE 13G/A: Nantahala Capital Management Discloses 9.99% Stake in UNICYCIVE THERAPEUTICS

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 9.99% in UNICYCIVE THERAPEUTICS, INC., totaling 12,243,386 shares.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (collectively, the "Reporting Persons") have filed a Schedule 13G, disclosing their beneficial ownership in UNICYCIVE THERAPEUTICS, INC.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 12,243,386 shares of Common Stock, representing 9.99% of the class.
• This aggregate amount includes 2,851,392 shares that may be acquired by the Reporting Persons within sixty days through the exercise of warrants.
• Nantahala Capital Management, LLC is classified as an Investment Adviser (IA), while Wilmot B. Harkey and Daniel Mack are classified as Control Persons (HC).
• The shares are held by funds and separately managed accounts under Nantahala's control, with shared voting and dispositive power among the Reporting Persons.

Sentiment

Score: 7

Explanation: The disclosure of a significant stake by an institutional investor is generally viewed positively, as it implies confidence in the company's value or future potential. However, this filing is purely a disclosure of ownership and does not contain operational or financial performance details of the issuer.

Positives

• A significant stake (9.99%) by an institutional investor like Nantahala Capital Management may signal confidence in UNICYCIVE THERAPEUTICS, INC.'s future prospects.
• The inclusion of warrants in the beneficial ownership calculation suggests potential for increased investment and long-term commitment.

Industry Context

This filing indicates a significant institutional investment in a biotechnology or pharmaceutical company, a common occurrence in the sector where specialized funds often take substantial positions in promising firms.

Related Party Transactions

• BLACKWELL PARTNERS LLC SERIES A, a fund advised by Nantahala Capital Management, LLC, has the right to receive or direct the receipt of dividends or proceeds from the sale of more than five percent of the outstanding common stock beneficially owned by Nantahala.

Stakeholder Impact

• Shareholders may view the significant institutional ownership as a positive signal, potentially increasing investor confidence and market stability.
• The presence of a large institutional investor could influence future strategic decisions or corporate governance, potentially aligning with long-term shareholder value.

Key Dates

Keywords

UNICYCIVE THERAPEUTICS, Nantahala Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Warrants, Institutional Investor